Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7385 - 7392 of 12089 results
Litigating standard-essential patents: recent developments
February 6, 2017| News
Crafting a growth strategy ahead of consolidation
February 6, 2017| News
An Energy Law Pioneer
February 6, 2017| News
URGENT UPDATE: Executive Order Travel Ban Lifted – At Least Temporarily
February 4, 2017| Alert| Viewpoint
Upcoming Event: EUCI's U.S./Canada Cross-Border Energy Trade Summit
February 3, 2017| Blog| Viewpoint
Supreme Court set to Decide this Term if Employees Can Waive Their Right to Bring a Class or Collective Action
February 3, 2017| Blog| Viewpoint
Federal Court of Australia Approves a Common Fund Class Action Model for the First Time - No Opt-In Required
February 2, 2017| Blog| Viewpoint
California Update: Amended Civil Code Section 1938 and New CASp Obligations for Commercial Landlords
February 2, 2017| Alert| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|